Global Topical Corticosteroids Market Size By Type (Class I, Class II), By Application (Treatment of Rash, Treatment of Eczema), By Region, And Segment Forecasts, 2023 to 2032

The Global Topical Corticosteroids Market was valued at USD 5.6 billion in 2023 and is projected to surpass USD 8.7 billion by 2031, growing at a CAGR of 5.7% during the forecast period from 2023 to 2031. The market growth is primarily driven by the rising prevalence of dermatological disorders, increasing awareness of skin health, and the growing use of corticosteroids in managing chronic inflammatory skin conditions such as eczema, psoriasis, and dermatitis. The ease of application, quick symptom relief, and widespread availability make topical corticosteroids a preferred treatment option across both over-the-counter and prescription segments.

Drivers:

1. Rising Incidence of Skin Disorders:

An increasing global burden of skin conditions—such as atopic dermatitis, contact dermatitis, and psoriasis—is significantly boosting demand for topical corticosteroids. These medications offer fast-acting anti-inflammatory effects, providing symptomatic relief and reducing healthcare costs related to more invasive treatments.

2. Expanding Geriatric Population:

Older adults are more susceptible to chronic skin issues due to natural aging and compromised immune responses. The growing aging population, especially in developed regions, is increasing the demand for topical corticosteroid therapies.

3. Growth in Over-the-Counter (OTC) Sales:

Greater awareness and self-medication trends have led to the rise in OTC corticosteroid creams and ointments. These products offer cost-effective, immediate solutions to common skin irritations and are being increasingly adopted, especially in regions with limited access to dermatologists.

Restraints:

1. Potential Side Effects and Misuse:

Long-term or unsupervised use of topical corticosteroids can lead to side effects like skin thinning, tachyphylaxis, and steroid-induced dermatitis, limiting their use and prompting regulatory restrictions.

2. Availability of Alternatives:

The growing preference for non-steroidal topical therapies, such as calcineurin inhibitors and newer biologics for severe cases, is presenting competition to corticosteroid formulations.

Opportunity:

1. Emerging Markets and Increasing Healthcare Access:

Expanding healthcare infrastructure in emerging markets, especially in Asia-Pacific and Africa, is opening new growth avenues. Increasing affordability and education about dermatological care are driving demand for topical corticosteroids in these regions.

2. Product Innovation and Combination Therapies:

Development of new formulations combining corticosteroids with antifungal or antibacterial agents, as well as innovations in drug delivery (e.g., liposomal or nano-based creams), are creating new market opportunities.

Market by System Type Insights:

The market is segmented by potency—Low, Medium, High, and Ultra-High. In 2023, the Medium Potency segment dominated, owing to its balanced efficacy and safety profile. These formulations are commonly prescribed for a wide range of conditions and offer versatility in treatment. However, the High Potency segment is expected to exhibit the fastest growth, driven by its effectiveness in treating severe dermatological cases.

Market by End-use Insights:

Hospitals and Dermatology Clinics emerged as the largest revenue contributors in 2023, driven by increasing patient inflow for chronic skin diseases and greater reliance on prescription-based corticosteroid therapies. The Retail Pharmacies and Drugstores segment is also growing steadily due to rising OTC sales, especially for mild corticosteroids.

Market by Regional Insights:

North America held the largest market share in 2023, supported by high healthcare spending, advanced dermatology infrastructure, and an increasing number of skin disorder cases. Asia-Pacific is anticipated to register the highest CAGR during the forecast period, fueled by improving healthcare access, a large patient pool, and growing awareness of skin conditions in countries like India and China.

Competitive Scenario:

Key players in the Global Topical Corticosteroids Market include:

GlaxoSmithKline plc

Bayer AG

Johnson & Johnson

LEO Pharma A/S

Perrigo Company plc

Cipla Inc.

Sun Pharmaceutical Industries Ltd.

Mylan N.V.

Taro Pharmaceutical Industries

Novartis AG

These companies are engaging in R&D initiatives, geographic expansion, and product portfolio diversification to maintain market competitiveness. For example:

In 2024, LEO Pharma launched a new combination corticosteroid cream targeting psoriasis and atopic dermatitis.

Perrigo expanded its OTC corticosteroid range in Europe in 2023 to meet growing demand for non-prescription skin care solutions.

Scope of Work – Global Topical Corticosteroids Market

Key Market Developments:

2023: Bayer AG expanded its dermatology product line in Southeast Asia, focusing on mid-potency corticosteroid formulations.

2024: GlaxoSmithKline received regulatory approval for a novel topical corticosteroid spray designed for faster absorption and prolonged relief.

2025: Johnson & Johnson launched a campaign promoting responsible use of OTC corticosteroids, aiming to boost consumer trust and product safety awareness.

FAQs:

1) What is the current market size of the Global Topical Corticosteroids Market?

The market was valued at USD 5.6 billion in 2023.

2) What is the major growth driver of the Global Topical Corticosteroids Market?

Rising prevalence of skin disorders and increasing demand for non-invasive dermatological treatments are key growth drivers.

3) Which is the largest region during the forecast period in the Global Topical Corticosteroids Market?

North America holds the largest market share.

4) Which segment accounted for the largest market share in the Global Topical Corticosteroids Market?

The Medium Potency segment dominated in 2023.

5) Who are the key market players in the Global Topical Corticosteroids Market?

Major players include GlaxoSmithKline, Bayer, Johnson & Johnson, LEO Pharma, and Cipla.